Certolizumab pegol is associated with long-term improvements in extra-articular manifestations of psoriatic arthritis over 4-years of treatment - 11/08/17
Oliver FitzGerald, Department of Rheumatology, St. Vincent’s University Hospital and Conway Institute; Roy Fleischmann, University of Texas SW Medical Center; Arthur Kavanaugh, Division of Rheumatology, Allergy & Immunology, UC San Diego; Bengt Hoepken, UCB Pharma; Luke Peterson, UCB Pharma; Dafna Gladman, Krembil Research Institute, Toronto Western Hospital
Le texte complet de cet article est disponible en PDF. Commercial support: This study was sponsored by UCB Pharma. Editorial and Medical Writing support for the abstract was provided by Costello Medical Consulting, which was sponsored by UCB Pharma. |
Vol 76 - N° 6S1
P. AB64 - juin 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?